Rigel Pharmaceuticals (STU:RI2A) Interest Expense : €-7.0 Mil (TTM As of Mar. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Rigel Pharmaceuticals Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Rigel Pharmaceuticals's interest expense for the three months ended in Mar. 2024 was € -1.7 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was €-7.0 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Rigel Pharmaceuticals's Operating Income for the three months ended in Mar. 2024 was € -6.4 Mil. Rigel Pharmaceuticals's Interest Expense for the three months ended in Mar. 2024 was € -1.7 Mil. Rigel Pharmaceuticals did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Rigel Pharmaceuticals Interest Expense Historical Data

The historical data trend for Rigel Pharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rigel Pharmaceuticals Interest Expense Chart

Rigel Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-0.30

-1.11

-4.30

-3.50

-6.30

Rigel Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-1.13	-1.72	-1.78	-1.75	-1.72

Rigel Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-7.0 Mil.

Rigel Pharmaceuticals (STU:RI2A) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Rigel Pharmaceuticals's Interest Expense for the three months ended in Mar. 2024 was €-1.7 Mil. Its Operating Income for the three months ended in Mar. 2024 was €-6.4 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was €41.4 Mil.

Rigel Pharmaceuticals's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Rigel Pharmaceuticals did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Rigel Pharmaceuticals (STU:RI2A) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rigel Pharmaceuticals Inc (STU:RI2A) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

RIGL:USA

Address

611 Gateway Boulevard, Suite 900, South San Francisco, CA, USA, 94080

Website

https://www.rigel.com

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility to develop and market the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Rigel Pharmaceuticals (STU:RI2A) Headlines

No Headlines